Theravance Biopharma, Inc. Debt Securities, Available-for-sale, Amortized Cost
Theravance Biopharma, Inc. (TBPH) had Debt Securities, Available-for-sale, Amortized Cost of $203.93 million as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Credit Losses › Credit Loss, Additional Improvements
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-11-12
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $203.93M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $332.32M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $124.46M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $58.02M; Debt Securities, Available-for-sale, Amortized Cost as first filed $58.57M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2025-09-30 | $203.93M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $332.32M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $124.46M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $58.02M 10-Q · filed 2025-11-12 | $58.57M 10-K · filed 2025-03-07 |
| 2024-09-30 | $82.59M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $86.53M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $75.38M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $89.13M 10-K · filed 2025-03-07 | |
| 2023-09-30 | $121.12M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $158.46M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $241.33M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $303.56M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $475.04M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $92.31M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $106.43M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $133.74M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $185.61M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $235.49M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $157.25M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $211.43M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $307.55M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $383.96M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $432.59M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $274.01M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $334.67M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $367.18M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $425.36M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $501.84M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $308.57M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $355.58M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $404.67M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $370.96M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |